Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Selective serotonin reuptake inhibitors (SSRIs) have become a cornerstone in treating depressive disorders. While the systemic consequences are well-understood, less is known about potential ocular side effects, specifically in relation to cataract development. To assess the prevalence of cataracts in patients on SSRIs compared to a control group not on these medications. A cross-sectional study was designed involving 300 patients aged 40 and over. They were categorized into two groups: 150 SSRI users with at least 2 years of consistent usage and 150 controls not on SSRIs. All participants underwent a detailed ophthalmological examination to ascertain the presence and severity of cataracts. Of the SSRI users, 48% were found to have cataracts compared to 32% in the control group. The odds ratio indicated that SSRI users had a 1.9 times higher likelihood of developing cataracts than those not on the medication. This study suggests that there may be a link between long-term SSRI usage and an increased risk of developing cataracts. Given the therapeutic importance of SSRIs, it's crucial to balance potential benefits with ocular risks.
How to cite this article:
Sailesh S. Katare, Hemant S. Todkar and Hemant J. Baxi. The Impact of SSRIs: Evaluating Cataract Prevalence in Antidepressant Users Through a Cross-Sectional Study.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.8.99.103
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.8.99.103